Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Non-Current Deffered Revenue (2016 - 2025)

Historic Non-Current Deffered Revenue for CytomX Therapeutics (CTMX) over the last 12 years, with Q3 2025 value amounting to $5.5 million.

  • CytomX Therapeutics' Non-Current Deffered Revenue fell 8349.92% to $5.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.5 million, marking a year-over-year decrease of 8349.92%. This contributed to the annual value of $26.9 million for FY2024, which is 6644.26% down from last year.
  • As of Q3 2025, CytomX Therapeutics' Non-Current Deffered Revenue stood at $5.5 million, which was down 8349.92% from $10.2 million recorded in Q2 2025.
  • CytomX Therapeutics' Non-Current Deffered Revenue's 5-year high stood at $267.8 million during Q1 2021, with a 5-year trough of $5.5 million in Q3 2025.
  • Over the past 5 years, CytomX Therapeutics' median Non-Current Deffered Revenue value was $140.9 million (recorded in 2023), while the average stood at $130.7 million.
  • As far as peak fluctuations go, CytomX Therapeutics' Non-Current Deffered Revenue surged by 2552.18% in 2021, and later crashed by 8349.92% in 2025.
  • Quarter analysis of 5 years shows CytomX Therapeutics' Non-Current Deffered Revenue stood at $243.9 million in 2021, then decreased by 26.19% to $180.1 million in 2022, then tumbled by 55.54% to $80.0 million in 2023, then crashed by 66.44% to $26.9 million in 2024, then crashed by 79.39% to $5.5 million in 2025.
  • Its Non-Current Deffered Revenue stands at $5.5 million for Q3 2025, versus $10.2 million for Q2 2025 and $16.2 million for Q1 2025.